Medindia

X

In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack

Monday, November 5, 2007 General News J E 4
Advertisement
TOKYO and INDIANAPOLIS, Nov. 4 In the pivotalPhase III head-to-head TRITON TIMI-38 clinical trial, the investigationalantiplatelet agent prasugrel produced a highly significant 19 percentreduction in relative risk (p=0.0004) for the composite endpoint ofcardiovascular death, non-fatal heart attack or non-fatal stroke when comparedwith clopidogrel (Plavix(R)/Iscover(R)) in the treatment of patients acrossthe full spectrum of acute coronary syndrome undergoing percutaneous coronaryintervention.

A significant reduction in the risk for the composite endpoint favoringprasugrel (60 mg loading dose/10 mg maintenance dose) over clopidogrel (300 mgLD/75 mg MD) was observed as early as three days. The absolute difference inthis endpoint continued to increase over the course of the 15-month, 13,608-patient trial.

In the important subgroup of patients with diabetes, prasugrel reduced therelative risk of cardiovascular death, non-fatal myocardial infarction andnon-fatal stroke by 30 percent (p<0.001). In addition, in the key secondaryendpoint of stent thrombosis, prasugrel reduced the recurrence of stentthrombosis (a new clot that develops at the stent site) by 52 percent(p<0.0001).

TRITON also showed that treatment with prasugrel significantly reduced therelative risk of cardiovascular death, non-fatal heart attack and non-fatalstroke by 21 percent in patients with STEMI (ST-elevation myocardialinfarction, or high-risk heart attack) (p=0.02) and 18 percent in patientssuffering from UA (unstable angina, or chest pain)/NSTEMI (non-STEMI)(p=0.002). In addition, prasugrel-treated patients experienced a 34 percentdecline in urgent target vessel revascularization (a procedure to reopenblocked arteries) (p<0.001) and a 42 percent reduction in heart attack withsubsequent death from cardiovascular causes (p=0.02).

While the overall incidence of non-CABG (coronary artery bypass grafting)bleeding in TRITON was low in both the prasugrel and clopidogrel treatmentgroups, prasugrel-treated patients experienced a statistically significantincrease in non-CABG (coronary artery bypass grafting) major bleeding comparedto clopidogrel-treated patients (2.4 vs. 1.8 percent, or 146 vs. 111 patients,p=0.03), including higher rates of life-threatening bleeding (1.4 vs. 0.9percent, or 85 vs. 56 patients, p=0.01). Though infrequent, fatal bleeding wasstatistically more frequent among prasugrel-treated than clopidogrel-treatedpatients (0.4 percent vs. 0.1 percent, or 21 vs. five patients, p=0.002).However, death from cardiovascular causes occurred less frequently amongprasugrel-treated patients than clopidogrel-treated patients (2.1 percent vs.2.4 percent, or 133 vs. 150 patients, p=0.31), as did all-cause death (3.0percent vs. 3.2 percent, or 188 vs. 197 patients, p=0.64).

The study identified three distinct patient subpopulations with a higherrisk of major bleeding in both treatment arms - patients who were 75 years ofage or older, weighed less than 60 kg (132 lbs.), or had a prior history oftransient ischemic attack (TIA) or stroke. Researchers are evaluatingpharmacokinetic data from several prasugrel studies, including TRITON, todetermine whether a lower dose of prasugrel might be appropriate for somepatients. Among patients without any of these risk factors (80 percent of the13,608-patient TRITON study), there was no significant difference in majorbleeding between prasugrel- and clopidogrel-treated patients (2 percent vs.1.5 percent, p=0.17).

Based on an analysis using the combined endpoint of all-cause death, heartattack, stroke and major bleeding, the net clinical benefit for prasugrelcompared with clopidogrel was a significant 13 percent reduction in overallevents (12.2 vs. 13.9, p=0.004). In the subpopulations defined as being atgreater risk of bleeding, the net clinical benefit was not different betweenprasugrel- and clopidogrel-treated patients
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Daiichi Sankyo, Lilly Announce New Prasugrel Head-...
S
Caliper Life Sciences' Third Quarter 2007 Financia...